537 related articles for article (PubMed ID: 18094383)
1. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
Leichtman AB
N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
[No Abstract] [Full Text] [Related]
2. Reduced exposure to calcineurin inhibitors in renal transplantation.
Ekberg H; Tedesco-Silva H; Demirbas A; Vítko S; Nashan B; Gürkan A; Margreiter R; Hugo C; Grinyó JM; Frei U; Vanrenterghem Y; Daloze P; Halloran PF;
N Engl J Med; 2007 Dec; 357(25):2562-75. PubMed ID: 18094377
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
[No Abstract] [Full Text] [Related]
4. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization.
Smith JM; Nemeth TL; McDonald RA
Pediatr Transplant; 2004 Oct; 8(5):445-53. PubMed ID: 15367279
[TBL] [Abstract][Full Text] [Related]
5. [Toward an evidence-based immunosuppression].
Pascual J
Nefrologia; 2001; 21(6):524-5; discussion 526-7. PubMed ID: 11881421
[No Abstract] [Full Text] [Related]
6. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
Ekberg H; Bernasconi C; Tedesco-Silva H; Vítko S; Hugo C; Demirbas A; Acevedo RR; Grinyó J; Frei U; Vanrenterghem Y; Daloze P; Halloran P
Am J Transplant; 2009 Aug; 9(8):1876-85. PubMed ID: 19563339
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Burke GW; Suzart K; Vaidya A; Roth D; Kupin W; Mattiazzi A; Rosen A; Esquenazi V; Miller J
Transplant Proc; 2003 Mar; 35(2):873-4. PubMed ID: 12644172
[No Abstract] [Full Text] [Related]
9. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen.
Vincenti F
Transplant Proc; 2001 Jun; 33(4 Suppl):11S-18S. PubMed ID: 11406263
[No Abstract] [Full Text] [Related]
10. [Immunosuppression for kidney transplant recipients: current strategies].
Alberú J; Urrea EM
Rev Invest Clin; 2005; 57(2):213-24. PubMed ID: 16524061
[TBL] [Abstract][Full Text] [Related]
11. The role of newer monoclonal antibodies in renal transplantation.
Vincenti F
Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
[No Abstract] [Full Text] [Related]
12. Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
Ciancio G; Miller A; Burke GW; Gharagozloo H; Rosen A; Roth D; Kupin W; Pinna A; Cespedes M; Esquenazi V; Miller J
Transplant Proc; 2001; 33(1-2):1013-4. PubMed ID: 11267169
[No Abstract] [Full Text] [Related]
13. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
14. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
[No Abstract] [Full Text] [Related]
15. [Immunossupresive drugs in renal transplantation].
Baczkowska T; Durlik M
Pol Arch Med Wewn; 2004 Oct; 112 Spec No():99-120. PubMed ID: 15669207
[TBL] [Abstract][Full Text] [Related]
16. Reduced exposure to calcineurin inhibitors in renal transplantation.
Krämer BK; Jung B; Banas B
N Engl J Med; 2008 Jun; 358(23):2519; author reply 2519-20. PubMed ID: 18536098
[No Abstract] [Full Text] [Related]
17. Can we maintain immunosuppression avoiding nephrotoxic agents in pancreas transplantation?
Kandaswamy R; Dunn T; Humar A; Sutherland DE
Transplant Proc; 2008 Mar; 40(2):516-7. PubMed ID: 18374118
[No Abstract] [Full Text] [Related]
18. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
[TBL] [Abstract][Full Text] [Related]
19. Inferior results with basis immunosuppression with sirolimus in kidney transplantation.
van den Akker JM; Hené RJ; Hoitsma AJ
Neth J Med; 2007 Jan; 65(1):23-8. PubMed ID: 17293636
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab as induction therapy in kidney and simultaneous pancreas-kidney transplantation.
Ciancio G; Mattiazzi A; Miller J; Burke GW
Minerva Urol Nefrol; 2003 Mar; 55(1):43-56. PubMed ID: 12773966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
